Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of Aripiprazole in Patients With Major Depressive Disorder

This study has been completed.
Sponsor:
Collaborator:
Otsuka America Pharmaceutical
Information provided by (Responsible Party):
Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier:
NCT00105196
First received: March 9, 2005
Last updated: November 7, 2013
Last verified: April 2011
Results First Received: March 27, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Diagnostic
Condition: Major Depressive Disorder
Interventions: Drug: Aripiprazole+ ADT
Drug: Placebo+ ADT

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
After initial screening period (7-28 days), subjects enrolled into an 8-wk prospective treatment phase (single-blind placebo plus an investigator-assigned, open-label, marketed antidepressant therapy [ADT]). Patients who met criteria for incomplete response at the end of this phase were randomized into the 6-wk double-blind phase in a 1:1 ratio.

Reporting Groups
  Description
Aripiprazole + ADT Subjects with a recorded baseline value at Week 8 and at least one recorded value on randomized study drug (aripiprazole). Missing baseline values were not imputed. Missing values on study drug were imputed using LOCF. Baseline values were not carried forward.
Placebo + ADT Subjects with a recorded baseline value at Week 8 and at least one recorded value on randomized study drug (placebo). Missing baseline values were not imputed. Missing values on study drug were imputed using LOCF. Baseline values were not carried forward.

Participant Flow:   Overall Study
    Aripiprazole + ADT   Placebo + ADT
STARTED   177   172 
COMPLETED   147   149 
NOT COMPLETED   30   23 
Lack of Efficacy                2                3 
Adverse Event                11                3 
Withdrawal by Subject                6                6 
Lost to Follow-up                3                2 
Poor/noncompliance                3                4 
Protocol Violation                5                2 
pending surgery                0                1 
marijuana use                0                1 
Subject became unblinded                0                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Aripiprazole + ADT Subjects with a recorded baseline value at Week 8 and at least one recorded value on randomized study drug (aripiprazole). Missing baseline values were not imputed. Missing values on study drug were imputed using LOCF. Baseline values were not carried forward.
Placebo + ADT Subjects with a recorded baseline value at Week 8 and at least one recorded value on randomized study drug (placebo). Missing baseline values were not imputed. Missing values on study drug were imputed using LOCF. Baseline values were not carried forward.
Total Total of all reporting groups

Baseline Measures
   Aripiprazole + ADT   Placebo + ADT   Total 
Overall Participants Analyzed 
[Units: Participants]
 177   172   349 
Age 
[Units: Years]
Mean (Standard Deviation)
 45.1  (10.6)   45.6  (11.3)   45.4  (10.9) 
Gender 
[Units: Participants]
     
Female   138   117   255 
Male   39   55   94 
Ethnicity (NIH/OMB) 
[Units: Participants]
     
Hispanic or Latino   6   6   12 
Not Hispanic or Latino   168   162   330 
Unknown or Not Reported   3   4   7 
Race/Ethnicity, Customized 
[Units: Participants]
     
American Indian or Alaska Native   0   1   1 
Asian   3   2   5 
Native Hawaiian or Other Pacific Islander   1   0   1 
Black or African American   14   18   32 
White   155   149   304 
Unknown or Not Reported   4   2   6 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Mean Change in the Montgomery Åsberg Depression Rating Scale (MADRS)   [ Time Frame: Baseline (Week 8) and Week 14 ]

2.  Secondary:   Mean Change in Sheehan Disability Scale (SDS) Mean Score   [ Time Frame: Baseline (Week 8) and Week 14 ]

3.  Secondary:   Mean Change in SDS Item Score (Social Life)   [ Time Frame: Baseline (Week 8) and Week 14 ]

4.  Secondary:   Mean Change in SDS Item Score (Family Life)   [ Time Frame: Baseline (Week 8) and Week 14 ]

5.  Secondary:   Mean Change in SDS Item Score (Work/School)   [ Time Frame: Baseline (Week 8) and Week 14 ]

6.  Other Pre-specified:   MADRS Response   [ Time Frame: Baseline (Week 8) and Week 14 ]

7.  Other Pre-specified:   Clinical Global Impression (CGI)-Improvement Response   [ Time Frame: Baseline (Week 8) and Week 14 ]

8.  Other Pre-specified:   MADRS Remission   [ Time Frame: Baseline (Week 8) and Week 14 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: BMS Study Director
Organization: Bristol-Myers Squibb
e-mail: Clinical.Trials@bms.com


Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier: NCT00105196     History of Changes
Other Study ID Numbers: CN138-165
Study First Received: March 9, 2005
Results First Received: March 27, 2009
Last Updated: November 7, 2013
Health Authority: United States: Food and Drug Administration